TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Core Viewpoint - TScan Therapeutics, Inc. has secured a significant investment of approximately $30 million from Lynx1 Capital Management LP, which reflects a 37% premium over the last closing price of its common stock, indicating strong investor confidence in the company's mission to develop TCR-T cell therapies for cancer treatment [1][5]. Company Overview - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [5][10]. - The company is developing its lead TCR-T therapy candidates for hematologic malignancies and has ongoing clinical trials, including the ALLOHATM Phase 1 heme trial and the PLEXI-TTM Phase 1 solid tumor trial [10]. Financial Details - The investment involves the sale of pre-funded warrants to purchase up to 7,500,000 shares of voting common stock at a price of $4.00 per warrant, with an exercise price of $0.0001 per share [5]. - Following this financing, the company expects its cash resources to fund operations into the first quarter of 2027, extending its financial runway beyond previous estimates [9].